Cancer Biomarkers Market

Cancer Biomarkers Market (Type: Protein, Genetics, and Others; and Type of Cancer: Lung, Breast, Leukemia, Melanoma, Colorectal, Prostate, Ovarian, Liver, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Cancer Biomarkers Market Outlook 2031

  • The global cancer biomarkers market was valued at US$ 12.6 Bn in 2021
  • The market is projected to advance at a CAGR of 9.9% from 2022 to 2031
  • The global cancer biomarkers market is anticipated to reach more than US$ 31.4 Bn by 2031

Analysts’ Viewpoint on Cancer Biomarkers Market Scenario

Cancer biomarkers play an important role in the early diagnosis of cancer and personalization of cancer treatments. Increase in prevalence of various types of cancers, rise in geriatric population across the world, and growth in technological advancements in development of cancer biomarkers are some of the key factors expected to drive the global cancer biomarkers market during the forecast period. Increase in usage of CEA biomarkers and HER2 biomarkers for detection of cancers such as breast cancer, ovary cancer, thyroid cancer, and small cell lung cancer is also projected to drive the market in the next few years. Leading players are focusing on research and development activities in biomarkers to gain lucrative revenue opportunities in the global cancer biomarkers market.

Cancer Biomarkers Market

Cancer Biomarkers Market Introduction

Biomarker, or biological marker, is a measurable indicator of some biological state or condition. Cancer biomarkers are biomolecules that can be used to determine the cancer in the body. According to the World Health Organization, cancer is a leading cause of death worldwide; it accounted for nearly 10 million deaths or nearly one in six deaths in 2020. Lung, breast, colon, rectum, and prostate cancers are some of the common cancers. According to a study published in the Journal of Ovarian Research, ovarian cancer is currently the fifth leading cause of death for women with cancer globally. More than 70% of cases of this cancer are diagnosed at an advanced stage. The human epididymis protein 4 biomarker test (HE4 test) is considered to be the most effective and reliable test for the detection of ovarian and endometrial cancers.

Request a sample to get extensive insights into the Cancer Biomarkers Market

Increase in Cancer Cases Worldwide to Drive Demand for Cancer Biomarkers

Wide prevalence of cancer is a key driver of the global cancer biomarkers market. According to a World Health Organization report, cancer is the major reason for deaths around the globe after heart issues. Cancer cases are surging due to the increase in trend of smoking, rise in pollution levels, and poor dietary habits. Around 235,760 lung cancer cases were reported in the U.S. in 2021. Furthermore, more than 130,000 people lose their lives every year due to lung cancer in the U.S. Lung cancer cases have been rising in other parts of the world as well, with percentage of people smoking reaching around 19% globally. Around one-third of deaths from cancer are linked to tobacco usage, high body mass index, alcohol consumption, low fruit and vegetable intake, and lack of physical activity. Cancer-causing infections, such as human papillomavirus (HPV) and hepatitis, are responsible for approximately 30% of cancer cases in low- and lower-middle-income countries.

Potential Pipeline Candidates to Offer Lucrative Opportunities to Market Vendors

Many pharmaceutical companies are actively investing in the research and development of novel biomarkers for cancer diagnosis and treatment. Various potential candidates are nearing the end of their development. This is expected to significantly boost the market. According to the National Library of Medicine, approximately 1,515 cancer biomarkers are in clinical trials. For instance, Lund University Hospital, in collaboration with the South Sweden Breast Cancer Group, is conducting clinical trials to compare the efficacy and tolerability of atorvastatin (in phase 2). Introduction of new biomarkers for cancer screening and diagnosis is expected to propel the oncology biomarkers market growth. Additionally, increase in product launches and diagnostics pertaining to cancer biomarkers is estimated to drive the market. For instance, in April 2021, F. Hoffmann-La Roche Ltd. (Switzerland) launched Elecsys Anti-p53 immunoassay to aid the diagnosis of various types of cancers.

Request a custom report on Cancer Biomarkers Market

Increase in Adoption of Protein Biomarkers for Accurate Diagnosis of Cancer

In terms of type, the global cancer biomarkers market has been classified into protein, genetic, and others. The protein segment held major share of the global market in 2021. The segment is expected to maintain its leading position in the global cancer biomarkers market during the forecast period. This can be ascribed to the increase in usage of protein biomarkers in research in cancer treatment. Protein biomarkers are considered the most common biomarkers used for the accurate detection of various types of cancers.

Rise in Incidence of Breast Cancer Across Globe

Based on type of cancer, the global cancer biomarkers market has been segmented into lung, breast, leukemia, melanoma, colorectal, prostate, ovarian, liver, and others. The breast cancer segment is projected to dominate the global market during the forecast period. Biomarkers are extensively used to detect breast cancer in patients. Increase in number of patients suffering from breast cancer across the globe is expected to drive the segment during the forecast period. According to the World Health Organization, breast cancer was the most common cancer across the globe in 2021, accounting for 12% of all new annual cancer cases worldwide.

High Efficiency of Omics Technology in Early Diagnosis of Cancer

In terms of profiling technology, the global cancer biomarkers market has been classified into omics, imaging, immunoassay, bioinformatics, and others. The omics segment held dominant share of the market in 2021. The segment is expected to grow at a faster pace during the forecast period. Omics technology is highly efficient in the early diagnosis of cancer. Additionally, novel development in profiling technologies for cancer biomarkers is expected to drive the cancer biomarker market size during the forecast period.

Regional Outlook of Global Cancer Biomarkers Market

North America dominated the global cancer biomarkers market, with more than 30% share in 2021. It is expected to hold major share of the global cancer biomarkers market during the forecast period. High patient population with cancer in the U.S. and Canada and increase in research and development activities in various types of cancer biomarkers are expected to drive the cancer biomarkers market in the region.

Europe is also expected to be a highly attractive region of the global cancer biomarkers market during the forecast period. Increase in prevalence and incidence of cancer in the region is likely to drive the market during the forecast period.

The cancer biomarkers market in Asia Pacific is also anticipated to grow significantly during the forecast period. This can be ascribed to the rise in disposable income, rapid urbanization, increase in health care infrastructure, and distribution and partnership strategies adopted by the players in the region.

Analysis of Key Players in Global Cancer Biomarkers Market

The global cancer biomarkers market is consolidated, with the top players accounting for major share. Players are focusing on adopting strategies such as acquisition & collaboration, geographic expansion, growth of distribution channels, and R&D to enhance their share in the global cancer biomarkers market. Key players operating in the global cancer biomarkers market are F. Hoffmann-La Roche Ltd., Abbott Laboratories, Merck & Co, Inc., Thermo Fisher Scientific, Inc., Bristol-Myers Squibb Company, PerkinElmer, Inc., Qiagen N.V., Siemens AG, Exact Sciences Corporation, Novartis AG, Bio-Rad Laboratories, Illumina, Agilent Technologies Inc., Hologic, Inc., and bioMérieux SA.

Key Developments in Global Cancer Biomarkers Market

  • In January 2022, a University of Oxford study published in the Clinical Cancer Research Journal defined a new type of blood test that can be used to detect a range of cancers and their spread throughout the body. The study had a sample size of 300 patients, with non-specific but concerning symptoms of cancer such as fatigue and weight loss. According to the study, cancer was correctly detected in 19 out of every 20 patients that used the test. In those with cancer, metastatic disease was identified with an overall accuracy of 94%.
  • In June 2021, Hill's Pet Nutrition announced plans to invest more than US$ 250 Mn in building a new factory in Leavenworth County in its home state of Kansas in order to cater to the rise in demand for its pet nutrition supplements
  • In December 2020, the FDA approved Thermo Fisher Scientific’s NGS-based companion diagnostic for EGFR Exon20 insertion mutant to help identify non-small cell lung cancer tumor tissue

Each of these players has been profiled in the cancer biomarkers market report based on parameters such as company overview, financial overview, business strategies, product portfolio, business segments, and recent developments.

Global Cancer Biomarkers Market Snapshot

Attribute

Detail

Market Size Value in 2021

US$ 12.6 Bn

Market Forecast Value in 2031

More than US$ 31.4 Bn

Growth Rate

(CAGR)

9.9%

Forecast Period

2022–2031

Historical Data Available for

2017–2020

Quantitative Units

US$ Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, and key trend analysis.

Competition Landscape

  • Market share analysis by the company (2021)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Type
    • Protein
    • Genetic
    • Others
  • Type of Cancer
    • Lung
    • Breast
    • Leukemia
    • Melanoma
    • Colorectal
    • Prostate
    • Ovarian
    • Liver
    • Others
  • Profiling Technology
    • Omics
    • Imaging
    • Immunoassay
    • Bioinformatics
    • Others
  • Application
    • Diagnostics
    • R&D
    • Prognostics
    • Others

Regions Covered

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Russia & CIS
  • Japan
  • China
  • India
  • ASEAN
  • Brazil
  • Mexico
  • GCC Countries
  • South Africa

Companies Profiled

  • F. Hoffmann-LA Roche Ltd.
  • Thermo Fisher Scientific, Inc.
  • Merck & Co, Inc.
  • Abbott Laboratories
  • Bristol-Myers Squibb Company
  • PerkinElmer, Inc.
  • Qiagen N.V.
  • Siemens AG
  • Exact Sciences Corporation
  • Novartis AG
  • Bio-Rad Laboratories
  • Illumina
  • Agilent Technologies Inc.
  • Hologic, Inc.
  • bioMérieux SA

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global cancer biomarkers market in 2021?

The global market was valued at US$ 12.6 Bn in 2021

How big will be the cancer biomarkers industry in 2031?

The industry is projected to reach more than US$ 31.4 Bn by 2031

What was the CAGR of the market from 2017–2021?

The global market grew at a CAGR of 4.5% from 2017 to 2021

What will be the CAGR of the global cancer biomarkers business during the forecast period (2022–2031)?

The global market is anticipated to grow at a CAGR of 9.9% from 2022 to 2031

Which are the prominent trends that affect the market growth?

Increase in patient population with various type of cancers, rise in geriatric population across the globe, and increase in technological advancements in development of cancer biomarkers

What was the market share of the leading segment of cancer biomarkers?

The protein type segment accounted for more than 50% share of the global market in 2021

Which region will account for the major share of the global market during the forecast period?

North America is expected to account for major share of the global cancer biomarkers market during the forecast period

Who are the prominent cancer biomarkers players?

F. Hoffmann-LA Roche Ltd., Thermo Fisher Scientific, Inc., Abbott Laboratories, Merck & Co., Inc Bristol-Myers Squibb Company, PerkinElmer, Inc., Qiagen N.V., Siemens AG, Exact Sciences Corporation, Novartis AG, Bio-Rad Laboratories, Illumina, Agilent Technologies Inc., Hologic, Inc., and bioMérieux SA

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Cancer Biomarkers Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Segment Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Cancer Biomarkers Market Analysis and Forecasts, 2017 - 2031

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. Technological Advancements

        5.2. Key Industry Events (Mergers, Acquisitions, Partnerships, etc.)

        5.3. Regulatory Scenario by Region/Globally

        5.4. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)

    6. Global Cancer Biomarkers Market Analysis and Forecasts, By Type

        6.1. Introduction & Definition

        6.2. Key Findings / Developments

        6.3. Market Value Forecast By Type, 2017 - 2031

            6.3.1. Protein

            6.3.2. Genetic

            6.3.3. Others

        6.4. Market Attractiveness By Type

    7. Global Cancer Biomarkers Market Analysis and Forecasts, By Type of Cancer

        7.1. Introduction & Definition

        7.2. Key Findings / Developments

        7.3. Market Value Forecast By Type of Cancer, 2017 - 2031

            7.3.1. Lung

            7.3.2. Breast

            7.3.3. Leukemia

            7.3.4. Melanoma

            7.3.5. Colorectal

            7.3.6. Prostate

            7.3.7. Ovarian

            7.3.8. Liver

            7.3.9. Others

        7.4. Market Attractiveness By Type of Cancer

    8. Global Cancer Biomarkers Market Analysis and Forecasts, By Profiling Technology

        8.1. Introduction & Definition

        8.2. Key Findings / Developments

        8.3. Market Value Forecast By Profiling Technology, 2017 - 2031

            8.3.1. Omics

            8.3.2. Imaging

            8.3.3. Immunoassay

            8.3.4. Bioinformatics

            8.3.5. Others

        8.4. Market Attractiveness By Profiling Technology

    9. Global Cancer Biomarkers Market Analysis and Forecasts, By Application

        9.1. Introduction & Definition

        9.2. Key Findings / Developments

        9.3. Market Value Forecast By Application, 2017 - 2031

            9.3.1. Diagnostics

            9.3.2. R&D

            9.3.3. Prognostics

            9.3.4. Others

        9.4. Market Attractiveness By Application

    10. Global Cancer Biomarkers Market Analysis and Forecasts, By Region

        10.1. Key Findings

        10.2. Market Value Forecast By Region

            10.2.1. North America

            10.2.2. Europe

            10.2.3. Asia Pacific

            10.2.4. Latin America

            10.2.5. Middle East & Africa

        10.3. Market Attractiveness By Country/Region

    11. North America Cancer Biomarkers Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Market Value Forecast By Type, 2017 - 2031

            11.2.1. Protein

            11.2.2. Genetic

            11.2.3. Others

        11.3. Market Value Forecast By Type of Cancer, 2017 - 2031

            11.3.1. Lung

            11.3.2. Breast

            11.3.3. Leukemia

            11.3.4. Melanoma

            11.3.5. Colorectal

            11.3.6. Prostate

            11.3.7. Ovarian

            11.3.8. Liver

            11.3.9. Others

        11.4. Market Value Forecast By Profiling Technology, 2017 - 2031

            11.4.1. Omics

            11.4.2. Imaging

            11.4.3. Immunoassay

            11.4.4. Bioinformatics

            11.4.5. Others

        11.5. Market Value Forecast By Application, 2017 - 2031

            11.5.1. Diagnostics

            11.5.2. R&D

            11.5.3. Prognostics

            11.5.4. Others

        11.6. Market Value Forecast By Country, 2017 - 2031

            11.6.1. U.S.

            11.6.2. Canada

        11.7. Market Attractiveness Analysis

            11.7.1. By Type

            11.7.2. By Type of Cancer

            11.7.3. By Profiling Technology

            11.7.4. By Application

            11.7.5. By Country

    12. Europe Cancer Biomarkers Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Market Value Forecast By Type, 2017 - 2031

            12.2.1. Protein

            12.2.2. Genetic

            12.2.3. Others

        12.3. Market Value Forecast By Type of Cancer, 2017 - 2031

            12.3.1. Lung

            12.3.2. Breast

            12.3.3. Leukemia

            12.3.4. Melanoma

            12.3.5. Colorectal

            12.3.6. Prostate

            12.3.7. Ovarian

            12.3.8. Liver

            12.3.9. Others

        12.4. Market Value Forecast By Profiling Technology, 2017 - 2031

            12.4.1. Omics

            12.4.2. Imaging

            12.4.3. Immunoassay

            12.4.4. Bioinformatics

            12.4.5. Others

        12.5. Market Value Forecast By Application, 2017 - 2031

            12.5.1. Diagnostics

            12.5.2. R&D

            12.5.3. Prognostics

            12.5.4. Others

        12.6. Market Value Forecast By Country/Sub-region, 2017 - 2031

            12.6.1. Germany

            12.6.2. U.K.

            12.6.3. France

            12.6.4. Spain

            12.6.5. Italy

            12.6.6. Rest of Europe

        12.7. Market Attractiveness Analysis

            12.7.1. By Type

            12.7.2. By Type of Cancer

            12.7.3. By Profiling Technology

            12.7.4. By Application

            12.7.5. By Country/Sub-region

    13. Asia Pacific Cancer Biomarkers Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Market Value Forecast By Type, 2017 - 2031

            13.2.1. Protein

            13.2.2. Genetic

            13.2.3. Others

        13.3. Market Value Forecast By Type of Cancer, 2017 - 2031

            13.3.1. Lung

            13.3.2. Breast

            13.3.3. Leukemia

            13.3.4. Melanoma

            13.3.5. Colorectal

            13.3.6. Prostate

            13.3.7. Ovarian

            13.3.8. Liver

            13.3.9. Others

        13.4. Market Value Forecast By Profiling Technology, 2017 - 2031

            13.4.1. Omics

            13.4.2. Imaging

            13.4.3. Immunoassay

            13.4.4. Bioinformatics

            13.4.5. Others

        13.5. Market Value Forecast By Application, 2017 - 2031

            13.5.1. Diagnostics

            13.5.2. R&D

            13.5.3. Prognostics

            13.5.4. Others

        13.6. Market Value Forecast By Country/Sub-region, 2017 - 2031

            13.6.1. China

            13.6.2. Japan

            13.6.3. India

            13.6.4. Australia & New Zealand

            13.6.5. Rest of Asia Pacific

        13.7. Market Attractiveness Analysis

            13.7.1. By Type

            13.7.2. By Type of Cancer

            13.7.3. By Profiling Technology

            13.7.4. By Application

            13.7.5. By Country/Sub-region

    14. Latin America Cancer Biomarkers Market Analysis and Forecast

        14.1. Introduction

            14.1.1. Key Findings

        14.2. Market Value Forecast By Type, 2017 - 2031

            14.2.1. Protein

            14.2.2. Genetic

            14.2.3. Others

        14.3. Market Value Forecast By Type of Cancer, 2017 - 2031

            14.3.1. Lung

            14.3.2. Breast

            14.3.3. Leukemia

            14.3.4. Melanoma

            14.3.5. Colorectal

            14.3.6. Prostate

            14.3.7. Ovarian

            14.3.8. Liver

            14.3.9. Others

        14.4. Market Value Forecast By Profiling Technology, 2017 - 2031

            14.4.1. Omics

            14.4.2. Imaging

            14.4.3. Immunoassay

            14.4.4. Bioinformatics

            14.4.5. Others

        14.5. Market Value Forecast By Application, 2017 - 2031

            14.5.1. Diagnostics

            14.5.2. R&D

            14.5.3. Prognostics

            14.5.4. Others

        14.6. Market Value Forecast By Country/Sub-region, 2017 - 2031

            14.6.1. Brazil

            14.6.2. Mexico

            14.6.3. Rest of Latin America

        14.7. Market Attractiveness Analysis

            14.7.1. By Type

            14.7.2. By Type of Cancer

            14.7.3. By Profiling Technology

            14.7.4. By Application

            14.7.5. By Country/Sub-region

    15. Middle East & Africa Cancer Biomarkers Market Analysis and Forecast

        15.1. Introduction

            15.1.1. Key Findings

        15.2. Market Value Forecast By Type, 2017 - 2031

            15.2.1. Protein

            15.2.2. Genetic

            15.2.3. Others

        15.3. Market Value Forecast By Type of Cancer, 2017 - 2031

            15.3.1. Lung

            15.3.2. Breast

            15.3.3. Leukemia

            15.3.4. Melanoma

            15.3.5. Colorectal

            15.3.6. Prostate

            15.3.7. Ovarian

            15.3.8. Liver

            15.3.9. Others

        15.4. Market Value Forecast By Profiling Technology, 2017 - 2031

            15.4.1. Omics

            15.4.2. Imaging

            15.4.3. Immunoassay

            15.4.4. Bioinformatics

            15.4.5. Others

        15.5. Market Value Forecast By Application, 2017 - 2031

            15.5.1. Diagnostics

            15.5.2. R&D

            15.5.3. Prognostics

            15.5.4. Others

        15.6. Market Value Forecast By Country/Sub-region, 2017 - 2031

            15.6.1. GCC Countries

            15.6.2. South Africa

            15.6.3. Rest of Middle East & Africa

        15.7. Market Attractiveness Analysis

            15.7.1. By Type

            15.7.2. By Type of Cancer

            15.7.3. By Profiling Technology

            15.7.4. By Application

            15.7.5. By Country/Sub-region

    16. Competition Landscape

        16.1. Market Player – Competition Matrix (By Tier and Size of companies)

        16.2. Market Share/Ranking Analysis By Company (2021)

        16.3. Company Profiles

            16.3.1. F. Hoffmann-LA Roche Ltd.

                16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.1.2. Product Portfolio

                16.3.1.3. SWOT Analysis

                16.3.1.4. Strategic Overview

            16.3.2. Thermo Fisher Scientific, Inc.

                16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.2.2. Product Portfolio

                16.3.2.3. SWOT Analysis

                16.3.2.4. Strategic Overview

            16.3.3. Abbott Laboratories

                16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.3.2. Product Portfolio

                16.3.3.3. SWOT Analysis

                16.3.3.4. Strategic Overview

            16.3.4. Bristol-Myers Squibb Company

                16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.4.2. Product Portfolio

                16.3.4.3. SWOT Analysis

                16.3.4.4. Strategic Overview

            16.3.5. PerkinElmer, Inc.

                16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.5.2. Product Portfolio

                16.3.5.3. SWOT Analysis

                16.3.5.4. Strategic Overview

            16.3.6. Qiagen N.V.

                16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.6.2. Product Portfolio

                16.3.6.3. SWOT Analysis

                16.3.6.4. Strategic Overview

            16.3.7. Siemens AG

                16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.7.2. Product Portfolio

                16.3.7.3. SWOT Analysis

                16.3.7.4. Strategic Overview

            16.3.8. Exact Sciences Corporation

                16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.8.2. Product Portfolio

                16.3.8.3. SWOT Analysis

                16.3.8.4. Strategic Overview

            16.3.9. Novartis AG

                16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.9.2. Product Portfolio

                16.3.9.3. SWOT Analysis

                16.3.9.4. Strategic Overview

            16.3.10. Bio-Rad Laboratories

                16.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.10.2. Product Portfolio

                16.3.10.3. SWOT Analysis

                16.3.10.4. Strategic Overview

            16.3.11. Illumina

                16.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.11.2. Product Portfolio

                16.3.11.3. SWOT Analysis

                16.3.11.4. Strategic Overview

            16.3.12. Agilent Technologies Inc.

                16.3.12.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.12.2. Product Portfolio

                16.3.12.3. SWOT Analysis

                16.3.12.4. Strategic Overview

            16.3.13. Hologic, Inc.

                16.3.13.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.13.2. Product Portfolio

                16.3.13.3. SWOT Analysis

                16.3.13.4. Strategic Overview

            16.3.14. bioMérieux SA

                16.3.14.1. Company Overview (HQ, Business Segments, Employee Strength)

                16.3.14.2. Product Portfolio

                16.3.14.3. SWOT Analysis

                16.3.14.4. Strategic Overview

    List of Tables

    Table 01: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

    Table 02: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

    Table 03: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 04: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 05: Global Cancer Biomarkers Market Value (US$ Mn) Forecast, by Region, 2017–2031

    Table 06: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country, 2017–2031

    Table 07: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

    Table 08: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

    Table 09: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 10: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 11: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-Region, 2017–2031

    Table 12: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

    Table 13: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

    Table 14: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 15: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 16: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

    Table 17: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

    Table 18: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

    Table 19: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 20: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 21: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 22: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

    Table 23: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

    Table 24: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 25: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    Table 26: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031

    Table 27: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type, 2017‒2031

    Table 28: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Type of Cancer, 2017–2031

    Table 29: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Technology, 2017–2031

    Table 30: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, by Application, 2017–2031

    List of Figures

    Figure 01: Global Cancer Biomarkers market Value (US$ Mn) Forecast, 2017–2031

    Figure 02: Global Cancer Biomarkers market Value Share, by Type, 2021

    Figure 03: Global Cancer Biomarkers market Value Share, by Profiling Technology, 2021

    Figure 04: Global Cancer Biomarkers market Value Share, by Cancer, 2021

    Figure 05: Global Cancer Biomarkers market Value Share, by Application, 2021

    Figure 06: Global Cancer Biomarkers market Value Share, by Region, 2021

    Figure 07: Global Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

    Figure 08: Global Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

    Figure 09: Global Cancer Biomarkers Market Value (US$ Mn), by Protein, 2017‒2031

    Figure 10: Global Cancer Biomarkers Market Value (US$ Mn), by Genetic, 2017‒2031

    Figure 11: Global Cancer Biomarkers Market Value (US$ Mn), by Others, 2017‒2031

    Figure 12: Global Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

    Figure 13: Global Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

    Figure 14: Global Cancer Biomarkers Market Revenue (US$ Mn), by Lung, 2017–2031

    Figure 15: Global Cancer Biomarkers Market Revenue (US$ Mn), by Breast, 2017–2031

    Figure 16: Global Cancer Biomarkers Market Revenue (US$ Mn), by Leukemia, 2017–2031

    Figure 17: Global Cancer Biomarkers Market Revenue (US$ Mn), by Melonoma, 2017–2031

    Figure 18: Global Cancer Biomarkers Market Revenue (US$ Mn), by Colorectal, 2017–2031

    Figure 19: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prostate, 2017–2031

    Figure 20: Global Cancer Biomarkers Market Revenue (US$ Mn), by Ovarian, 2017–2031

    Figure 21: Global Cancer Biomarkers Market Revenue (US$ Mn), by Liver, 2017–2031

    Figure 22: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 23: Global Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 24: Global Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 25: Global Cancer Biomarkers Market Revenue (US$ Mn), by Omics, 2017–2031

    Figure 26: Global Cancer Biomarkers Market Revenue (US$ Mn), by Imaging, 2017–2031

    Figure 27: Global Cancer Biomarkers Market Revenue (US$ Mn), by Immunoassay, 2017–2031

    Figure 28: Global Cancer Biomarkers Market Revenue (US$ Mn), by Bioinformatics, 2017–2031

    Figure 29: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 30: Global Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 31: Global Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

    Figure 32: Global Cancer Biomarkers Market Revenue (US$ Mn), by Diagnostics, 2017–2031

    Figure 33: Global Cancer Biomarkers Market Revenue (US$ Mn), by R&D, 2017–2031

    Figure 34: Global Cancer Biomarkers Market Revenue (US$ Mn), by Prognostics, 2017–2031

    Figure 35: Global Cancer Biomarkers Market Revenue (US$ Mn), by Others, 2017–2031

    Figure 36: Global Cancer Biomarkers Market Value Share Analysis, by Region, 2021 and 2031

    Figure 37: Global Cancer Biomarkers Market Attractiveness Analysis, by Region, 2022–2031

    Figure 38: North America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

    Figure 39: North America Cancer Biomarkers Market Value Share Analysis, by Country, 2021 and 2031

    Figure 40: North America Cancer Biomarkers Market Attractiveness Analysis, by Country, 2022–2031 

    Figure 41: North America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

    Figure 42: North America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

    Figure 43: North America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

    Figure 44: North America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

    Figure 45: North America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 46: North America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 47: North America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 48: North America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

    Figure 49: Europe Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

    Figure 50: Europe Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 51: Europe Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 52: Europe Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

    Figure53 11: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

    Figure 54: Europe Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

    Figure 55: Europe Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

    Figure 56: Europe Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 57: Europe Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 58: Europe Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 59: Europe Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

    Figure 60: Asia Pacific Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

    Figure 61: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Country/Sub-region, 2021 and 2031

    Figure 62: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-region, 2022–2031

    Figure 63: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

    Figure 64: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

    Figure 65: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

    Figure 66: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

    Figure 67: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 68: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 69: Asia Pacific Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 70: Asia Pacific Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

    Figure 71: Latin America Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

    Figure 72: Latin America Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031

    Figure 73: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

    Figure 74: Latin America Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

    Figure 75: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

    Figure 76: Latin America Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

    Figure 77: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

    Figure 78: Latin America Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 79: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 80: Latin America Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 81: Latin America Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

    Figure 82: Middle East & Africa Cancer Biomarkers Market Value (US$ Mn) Forecast, 2017–2031

    Figure 83: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Country/Sub-Region, 2021 and 2031

    Figure 84: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Country/Sub-Region, 2021-2031

    Figure 85: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type, 2021 and 2031

    Figure 86: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type, 2022–2031

    Figure 87: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Type of Cancer, 2021 and 2031

    Figure 88: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Type of Cancer, 2022–2031

    Figure 89: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Technology, 2021 and 2031

    Figure 90: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Technology, 2022–2031

    Figure 91: Middle East & Africa Cancer Biomarkers Market Value Share Analysis, by Application, 2021 and 2031

    Figure 92: Middle East & Africa Cancer Biomarkers Market Attractiveness Analysis, by Application, 2022–2031

Copyright © Transparency Market Research, Inc. All Rights reserved